在接受体外膜氧化 (ECMO) 治疗的重症患者中,Cefiderocol的药理动力学
Christina Koenig1, Andrew J Fratoni2, Yasmeen Abouelhassan2
1Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, Connecticut, USA; Department of Intensive Care Medicine, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
International journal of antimicrobial agents
|February 19, 2025
概括
在身体外膜氧化 (ECMO) 的重症患者中,标准的塞菲德罗科尔剂量实现了最佳的抗菌暴露. 这项研究证实,目前的建议确保100%实现对敏感细菌的目标.
科学领域:
- 药理学 药理学是指药理学的学科.
- 关键护理医学 关键护理医学
- 传染性疾病 传染性疾病
背景情况:
- 身体外膜氧化 (ECMO) 在重症患者中显著改变药物的药理动力学.
- 了解CEFIDEROCOL在ECMO期间的行为对于有效治疗严重感染至关重要.
研究的目的:
- 在接受ECMO的重症患者中评估Cefiderocol的药理动力学.
- 为了确定标准的 cefiderocol 剂量方案是否能达到足够的药物暴露.
主要方法:
- 在ECMO治疗的5名重症患者中对Cefiderocol的药理动力学分析.
- 基于肌素清除的剂量;在稳定状态下取血样.
- 评估超过最小抑制度 (fT>MIC) 的时间百分比和曲线下的面积 (AUC).
主要成果:
- 标准的塞菲德罗科尔剂量 (1.5g q8h至2g q6h) 达到100%的fT>MIC,所有患者最多16mg/L.
- 平均蛋白质结合率为41%.
- 稳定状态AUC24h与非ECMO患者相比.
结论:
- 这是第一个详细介绍ECMO患者中Cefiderocol药理动学的研究.
- 目前对CEFIDEROCOL的剂量建议是有效的,并且在ECMO治疗的重症患者中耐受良好.
- 标准剂量确保了最佳的 cefiderocol 暴露,类似于非ECMO 种群.
更多相关视频
11:15Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations
Published on: July 24, 2021
4.5K
09:26Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung
Published on: January 22, 2021
6.8K
相关概念视频
01:11Renal Failure: Dose Adjustments
60
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
60
01:29Acute Respiratory Failure-V
114
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Ensure that patients are monitored continuously for their response to therapy, including changes in...
114